The Drug Revolving Fund (DRF) represents a financing mechanism designed to improve the availability and affordability of essential medicines in resource-limited settings. This essay examines the DRF in The Gambia, exploring its background, operational processes, key components, achievements to date, and ongoing challenges. It draws on established principles of health financing to evaluate the factors critical for successful implementation, highlighting both opportunities and limitations within the Gambian context.
Background of Drug Revolving Fund (DRF) in The Gambia
The DRF was introduced in The Gambia during the 1990s as part of broader health sector reforms aimed at addressing chronic shortages of pharmaceuticals in public facilities. Influenced by World Health Organization recommendations on sustainable drug supply systems, the initiative sought to move away from reliance on donor funding toward a self-sustaining model. Limited public data indicate that the scheme was piloted in selected health centres before gradual national rollout, reflecting efforts to align with primary health care goals under the Bamako Initiative framework.
How Drug Revolving Fund (DRF) works in the Gambia
In practice, the DRF operates by charging nominal fees for medicines at government health facilities, with revenues reinvested to procure replacement stock. Patients pay a small markup on drugs, creating a continuous cycle of funds that supports regular supply without full cost recovery. This user-fee element is typically managed at facility level, with oversight from district health teams to ensure transparency in accounting and stock management. Proceeds are deposited into dedicated accounts and used exclusively for medicine replenishment, thereby reducing dependence on irregular government or donor budgets.
Key components of Drug Revolving Fund (DRF) Implementation
Successful DRF implementation in The Gambia rests on several interrelated components: reliable procurement systems, accurate inventory tracking, trained personnel for financial management, community engagement to foster acceptance of fees, and regular monitoring to prevent leakage or misuse of funds. These elements must function cohesively to maintain medicine availability while keeping costs affordable for low-income populations.
Achievements of DRF in The Gambia since its inception
Despite data constraints, the DRF has contributed to modest improvements in medicine availability at primary care level and generated supplementary revenue for some facilities. It has also encouraged greater accountability in drug management and raised awareness among health workers about the importance of efficient stock control. These outcomes align with broader evidence from similar schemes in sub-Saharan Africa.
Major challenges in the implementation of DRF in the Gambia
Persistent challenges include irregular fee collection, inflation-driven rises in procurement costs, weak supply-chain infrastructure, and limited capacity for financial oversight at peripheral facilities. Socioeconomic barriers sometimes lead to delayed treatment when patients cannot afford even modest charges, undermining the equity objectives of the scheme. Additionally, political and administrative turnover can disrupt continuity in programme management.
Factors needed for a successful implementation of DRF
Long-term sustainability requires strong governance, regular training for health facility staff, integration with national health insurance mechanisms, and transparent auditing. Community sensitisation, flexible fee exemptions for vulnerable groups, and linkages to donor-supported technical assistance also enhance viability. Without these supports, the DRF risks reverting to the very supply interruptions it was intended to resolve.
In conclusion, the DRF in The Gambia illustrates both the promise and the complexities of revolving drug funds in low-resource environments. While it has delivered incremental gains in medicine access, structural and operational weaknesses continue to limit its impact. Strengthening governance and aligning the scheme with wider health financing reforms remain essential for realising its full potential.
References
- World Health Organization. (2000) The Bamako Initiative: Lessons from Implementation. World Health Organization.
- McPake, B. et al. (1993) Community financing of health care in Africa: an evaluation of the Bamako Initiative. Social Science & Medicine, 36(11), pp. 1383–1395.
